Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.



  • FDA Approves Pralsetinib for RET Fusion–Positive NSCLC

    FDA Approves Pralsetinib for RET Fusion–Positive NSCLC

    Industry News & Regulatory Approvals

    The US Food and Drug Administration (FDA) granted Accelerated Approval to pralsetinib as treatment for adults with metastatic NSCLC who harbor RET fusions. The first and only test to identify RET fusion–positive NSCLC, the Oncomine Dx Target Test, was granted premarket approval as a companion diagnostic for pralsetinib therapy. The test will be updated to report RET fusions by early 2021 in the United States. Pralsetinib’s approval…


  • Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies

    Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies

    Evolving Standards of Care

    By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a single disease: HER2 gene amplification with breast cancer, BCR-ABL fusions with chronic myelogenous leukemia, EGFR mutations with lung cancer, and BRAF mutations with melanoma. Thus,…